SCHEMBL3198076

SCHEMBL3198076

N[C@@H]1CC2CCN1CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3351081 1.00
SCHEMBL492073 1.00
Hydrochloric Acid SCHEMBL29131455 0.97
Hydrochloric Acid SCHEMBL2346747 0.97
Hydrochloric Acid SCHEMBL2349412 0.97
Hydrochloric Acid SCHEMBL1090593 0.97
SCHEMBL22732393 0.82
SCHEMBL3207004 0.82
SCHEMBL2148328 0.69
SCHEMBL4279010 0.67 SLC18A3 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142428-A1 Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof NOVARTIS AG (CH) 2007-06-21 US claimed
CN-115703777-B Separation method of 3-quinuclidinone 上海医药工业研究院 2025-03-21 CN disclosed
US-10611793-B1 Solid state forms of obeticholic acid salts TEVA CZECH INDUSTRIES S.R.O. (CZ) 2020-04-07 US disclosed
EP-3016642-A1 METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) (AU) 2016-05-11 EP disclosed
WO-2015000032-A1 METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) 2015-01-08 WO disclosed
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-7683075-B2 Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof NOVARTIS AG (CH) 2010-03-23 US disclosed
EP-1558610-B1 SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2008-02-27 EP disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-20070142428-A1 Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof NOVARTIS AG (CH) 2007-06-21 US disclosed
EP-1558610-A2 SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-08-03 EP disclosed
WO-2004099206-A1 ISOQUINOLINE-3-CARBOXYLIC ACID AMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-11-18 WO disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
US-20040110789-A1 Substituted aminoquinuclidine compounds BOYD ROBERT E (US) 2004-06-10 US disclosed
WO-2004035574-A2 SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-04-29 WO disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed
EP-1025109-A1 BENZOXAZINE DERIVATIVES, PREPARATION AND APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 2000-08-09 EP disclosed
WO-1999020633-A1 BENZOXAZINE DERIVATIVES, PREPARATION AND APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 1999-04-29 WO disclosed
US-5721251-A INCREASING SECRETION OF GROWTH HORMONE IN HUMANS AND ANIMALS MERCK & CO., INC. (US) 1998-02-24 US disclosed